Skip to main content

UNC Lineberger member Andrew Wang, MD, an associate professor in the UNC School of Medicine Department of Radiation Oncology, is a medical adviser for the startup ECF Biosolutions. The company, in conjunction withCarillion BioPharma, was announced as a winner of an Innovation Excellence Award through the Nanotechnology Startup Challenge in Cancer.

image2
Andrew Wang, MD, is a UNC Lineberger member and an associate professor in the UNC School of Medicine Department of Radiation Oncology.

A startup company advised by a UNC Lineberger researcher was announced as one of 10 winners of the Nanotechnology Startup Challenge in Cancer by the Center for Advancing Innovation.

UNC Lineberger member Andrew Wang, MD, an associate professor in the UNC School of Medicine Department of Radiation Oncology, is a medical adviser for the startup ECF Biosolutions. The company, in conjunction with Carillion BioPharma, was announced as a winner of an Innovation Excellence Award.

According to a news release about the winners, the challenge featured inventions discovered and advanced by scientists from three participating institutes of the National Institutes of Health (NIH) as well as by extramural, “third-party” groups outside of the NIH.

The winning entrepreneurs were selected based on 10-page business plans, financial models, and 20-minute “live pitches” to a panel of expert judges.

Winning teams will move forward to the third and final phase of the challenge – the Startup Phase. In this phase, the winning teams will form their startups to advance cancer nanotechnology inventions.

Teams, including ECF Biosolutions, that received the Innovation Excellence Award will receive a $2,000 cash award. All teams that were accepted into the challenge were placed in an accelerator program with a rigorous advancement process, which was independent from the inventions they chose, and only those teams who met the criteria advanced to Phase 2.